All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2020-08-06.
From the record
NovoCure Limited's filings since 2017 show 1 warning event: a debt default or acceleration notice (8-K item 2.04, the latest 2020-08-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+25.8% a year over 10 filed years; profitable in 1 of 10.
From the record
NovoCure Limited's 10 filed years say what it did: revenue went from $83 million in fiscal 2016 to $655 million in fiscal 2025, up 25.8% a year; it rose in 8 of 9 years; the deepest fall was 5% from fiscal 2022 to fiscal 2023; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: NovoCure Limited's shareholder treatment is put at 6.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 34% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -40%: lost 40¢ per shareholder dollar. Leverage 58%: owes 58¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, NovoCure Limited lost about 40 cents for every dollar of shareholders' money, and gross profitability: its products earned about 61 cents per dollar of everything the company owns. Leverage: it owed about 58 cents per dollar of assets, and net share issuance: its share count grew 3.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 45% of 109 in its family; net margin -20.8%.
From the record
NovoCure Limited's standing among 109 graded names in its industry family: revenue of $655 million in fiscal 2025 ranks in the top 24% by size; a net margin of -20.8% ranks in the top 49%; revenue growth of 6.8% a year over the last 3 filed years ranks in the bottom 36% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 39% of 91 in its family for leadership; chief executive since 2026.
From the record
NovoCure Limited's leadership, from its insiders' filings and its current reports: the chief executive on the record is Leonard, Frank X (Chief Executive Officer, as filed), filing under that title since 2026-03-03, 8 months (bottom 14% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 6.2 years (top 37%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 45% of 104 in its family for room to expand.
From the record
NovoCure Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $94 million against debt of $195 million leaves -12.6% of its assets as net cash, bottom 25% of its family; cash from operations less capital spending is -11.5% of revenue (bottom 48%); a gross margin of 74.5% (top 24%); research spending of 34.3% of revenue (top 27%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 39% of 105 in its family for growth drivers.
From the record
NovoCure Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 6.8% a year over the last three filed years against 25.8% over all 10, slowing (bottom 17% of its family); the newest year grew 8.3% (bottom 37%); research spending grew 2.9% a year (bottom 42%); capital spending grew 7.7% a year (top 40%) (its annual reports). NovoCure Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 48% of 88 in its family for expectations against reality.
From the record
NovoCure Limited's newest year against its own record: revenue of $655 million in fiscal 2025 came in 2.1% above the $642 million its prior three years' pace pointed to (top 34% of its family); net income of $136 million against a prior three-year average of $156 million (bottom 46%); a net margin of -20.8% against -28.6% before (bottom 46%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made